Europe's Gene Therapy Sector at a Crossroads
Europe has a window to attract biologics and mRNA manufacturers amid US policy shifts, but it needs to act faster on high-skill immigration and AI policy. This opportunity is tempered by ongoing challenges within its gene therapy sector, which struggles with harmonizing regulatory frameworks and scaling manufacturing to compete with the US and Asia.
The European Union's new regulation on health technology assessments (HTA) will mandate joint clinical assessments (JCAs) for all advanced therapy medicinal products (ATMPs), including gene therapies, starting in 2025. This aims to harmonize evaluation across member states but adds a new layer of complexity for developers accustomed to navigating disparate national reimbursement systems. A significant overhaul of EU pharmaceutical legislation proposes integrating the Committee for Advanced Therapies (CAT) into the broader Committee for Medicinal Products for Human Use (CHMP) to streamline processes. This move coincides with efforts by the European Commission and EMA to optimize the regulatory environment without major legal changes, focusing on updated guidelines for good manufacturing practices (GMP) and addressing inconsistencies in rules for genetically modified organisms (GMOs). The European cell and gene therapy CDMO market, which generated over $1.5 billion in 2024, is projected to grow at a CAGR of 23.3% through 2033. Germany is expected to dominate this market, leveraging its advanced research facilities and skilled workforce, with key players including Catalent, Lonza, and WuXi Advanced Therapies. This growth is fueled by an increasing reliance on CDMOs to provide specialized expertise in process development and manufacturing. Despite regulatory streamlining, European ATMP developers face a challenging funding environment, with a significant drop in venture capital deals since the peak in 2021. This has led to a more selective investment landscape, favoring de-risked projects and later-stage financing, while some major pharmaceutical companies have scaled back their internal cell therapy research. To accelerate development, the European Commission launched a €1.1 billion "Apply AI" initiative, establishing AI health hubs and regulatory sandboxes for trialing AI-driven therapies. This is complemented by a proposed European Biotech Act aimed at fast-tracking AI-enabled therapies and supporting bio-manufacturing. In January 2026, the EMA and FDA jointly established principles for good AI practice in medicine development to reduce regulatory divergence. A primary technical hurdle remains the shift from adherent to suspension cell culture systems for viral vector production, which is essential for scaling up to commercial volumes and reducing contamination risks. This transition is critical for improving process economics but requires significant process development to manage impurities and ensure product comparability, a key focus for regulators. The lack of process standardization across the industry further complicates technology transfer from research to GMP manufacturing environments. Digital twins are emerging as a key Pharma 4.0 technology to de-risk manufacturing scale-up, enabling virtual process optimization and predictive maintenance before implementation on the factory floor. By integrating real-time data from IoT sensors, these models help maintain quality control, reduce downtime, and ensure robust, traceable records for GMP compliance and regulatory audits. This aligns with the industry's need for better data management systems to connect isolated data silos like LIMS, MES, and ERPs for a holistic view of the manufacturing process.
